TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

分组1 - TScan Therapeutics reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.27, representing an earnings surprise of +34.31% [1] - The company posted revenues of $2.57 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 37.08%, compared to revenues of $0.67 million a year ago [2] - TScan Therapeutics shares have increased by approximately 3.5% since the beginning of the year, while the S&P 500 has declined by 0.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $2.5 million, and for the current fiscal year, it is -$0.99 on revenues of $9.42 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 44% of over 250 Zacks industries, indicating potential challenges for the sector [8]